Expanded Access to Venetoclax

Sponsor
AbbVie (Industry)
Overall Status
Available
CT.gov ID
NCT03123029
Collaborator
(none)

Study Details

Study Description

Brief Summary

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Venetoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Study Design

Study Type:
Expanded Access
Official Title:
Expanded Access to Venetoclax

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • The participant must not be eligible for a venetoclax clinical trial.

    • Pediatric participants may be evaluated on a case by case basis.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • AbbVie

    Investigators

    • Study Director: ABBVIE INC., AbbVie

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    AbbVie
    ClinicalTrials.gov Identifier:
    NCT03123029
    Other Study ID Numbers:
    • C16-431
    • C19-920
    First Posted:
    Apr 21, 2017
    Last Update Posted:
    Mar 29, 2022
    Last Verified:
    Mar 1, 2022

    Study Results

    No Results Posted as of Mar 29, 2022